Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis

Autor: Laura E. Schultz‐Rogers, Michelle L. Thayer, Sekhar Kambakam, Wesley A. Wierson, Jordan A. Helmer, Mark D. Wishman, Kristen A. Wall, Jessica L. Greig, Jaimie L. Forsman, Kavya Puchhalapalli, Siddharth Nair, Trevor J. Weiss, Jon M. Luiken, Patrick R. Blackburn, Stephen C. Ekker, Marcel Kool, Maura McGrail

Publikováno v: Developmental Dynamics. 251:1267-1290

Retinoblastoma binding protein 4 (Rbbp4) is a component of transcription regulatory complexes that control cell cycle gene expression. Previous work indicated that Rbbp4 cooperates with the Rb tumor suppressor to block cell cycle entry. Here, we use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914497a99fae0f1b87a9d128367c08bc
https://doi.org/10.1002/dvdy.467

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author response for 'Metformin and carotid intima media thickness in never smokers with type 1 diabetes: the REMOVAL trial'

Autor: null JG Timmons, null N Greenlaw, null JG Boyle, null N Chaturvedi, null I Ford, null MCGJ Brouwers, null T Tillin, null I Hramiak, null AD Hughes, null AJ Jenkins, null BEK Klein, null R Klein, null TC Ooi, null P Rossing, null CDA Stehouwer, null N Sattar, null HM Colhoun, null JR Petrie, null A Hughes, null A Jenkins, null H Nickerson, null O Lou, null S Dutta, null Jonathan Haw, null Carol Anderson, null S Kean, null E Thomson, null L Gillespie, null J Gibb, null A Keech, null K March, null S Williams, null E Coady, null M Bots, null B Klein, null J Dreyer, null T Jan, null Koby Sheffy, null Ravit Lusky, null Shlomit Peleg, null J Petrie, null H Colhoun, null A Shore, null D Carty, null P Donnan, null M Witham, null A Adler, null E Lonn, null P Rauchhaus, null R Lindsay, null M Brouwers, null J Van‐Melckebeke, null T Hamill, null L Cuthbertson, null A Murray, null L Jolly, null E Miller, null J Hair, null A Bell, null S Carmichael, null E Douglas, null P Surtees, null E Dinnett, null J Allan, null C Watson, null M McLaughlin, null G Brindley, null E Smillie, null D Motherwell, null S MacDonald, null P Ellis, null D Stuart, null M Travers, null S Brearley, null L Greig, null P Colman, null D West, null S Vaughan, null M Bjorasen, null J Donlan, null J Vrazas, null D O'Neal, null J Horsburgh, null S Kent, null S Twigg, null G Fulcher, null R Denner, null A Piotrowicz, null A Januszewski, null H Pater, null A Coy, null T Paul, null C McDonald, null S Tereschyn, null N Schmidt, null M Weingert, null H Heard, null S Burke, null H Lochnan, null A Sorisky, null E Keely, null J Malcolm, null J Maranger, null C Favreau, null S Petherick, null K Boles, null TW Hansen, null B Hemmingsen, null N Thorogood, null K Green, null T Robinson, null K Abouglilia, null D Nayman, null C Miller, null R Warren, null K Aizawa, null M Balasubramani, null S Toth, null K Harvey, null G Birch, null T Sathyapalan, null A James, null Z Javed, null J Wilding, null B Martin, null S Birch, null A Wilcox, null N Watson, null N Oliver, null N Jugnee, null M Rutter, null T Turgut, null A Shaju, null S Yau, null S Subin, null M Walker, null D Wake, null A Millward, null P Chong, null M Hibbert, null N Schaper, null J Pinxt, null S Philip L Murray, null Linda Sleigh, null K Allan, null J Cook, null K Campbell, null L Hodge, null G Leese, null G Reekie, null K Shields, null A Jaap, null A Sudworth, null A White, null J McKnight, null L Steven, null G McKay, null A Llano, null G Currie, null E Lennon, null J Johnstone, null for the REMOVAL Study Group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55b8ba92b6d72b6e2e19fc362141545d
https://doi.org/10.1111/dom.14350/v2/response1

Intravenous minocycline in multidrug-resistant infections: a profile of its use in the USA with a focus on Acinetobacter infections

Autor: Sarah L. Greig, Katherine A. Lyseng-Williamson, Lesley J. Scott

Publikováno v: Drugs & Therapy Perspectives. 33:555-565

Intravenous (IV) minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of many bacteria (e.g. Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp.). Minocycl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::31f382b9bd665d945ac1f25cd9d45108
https://doi.org/10.1007/s40267-017-0453-3

Brodalumab: First Global Approval

Autor: Sarah L. Greig

Publikováno v: Drugs. 76:1403-1412

Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6618dc9f699990a2b8a5fc2690e28560
https://doi.org/10.1007/s40265-016-0634-8